scholarly journals Dual electrochemical sensing of spiked virus and SARS-CoV-2 using natural bed-receptor (MV-gal1)

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
E. Ghazizadeh ◽  
Ali Neshastehriz ◽  
Ali Dehghani Firoozabadi ◽  
Mohammad Kaji Yazdi ◽  
Esmail Saievar-Iranizad ◽  
...  
Keyword(s):  
Point Of Care ◽  
Electrochemical Sensing ◽  
Specific Detection ◽  
Early Screening ◽  
Lectin Receptor ◽  
Point Of Care Test ◽  
Viral Particles ◽  
The One ◽  
First Time ◽  
Natural Bed

AbstractIt has been necessary to use methods that can detect the specificity of a virus during virus screening. In this study, we use a dual platform to identify any spiked virus and specific SARS-CoV-2 antigen, sequentially. We introduce a natural bed-receptor surface as Microparticle Vesicle-Galactins1 (MV-gal1) with the ability of glycan binding to screen every spiked virus. MV are the native vesicles which may have the gal-1 receptor. Gal-1 is the one of lectin receptor which can bind to glycan. After dropping the MV-gal1 on the SCPE/GNP, the sensor is turned on due to the increased electrochemical exchange with [Fe(CN)6]−3/−4 probe. Dropping the viral particles of SARS-CoV-2 cause to turn off the sensor with covering the sugar bond (early screening). Then, with the addition of Au/Antibody-SARS-CoV-2 on the MV-gal1@SARS-CoV-2 Antigen, the sensor is turned on again due to the electrochemical amplifier of AuNP (specific detection).For the first time, our sensor has the capacity of screening of any spike virus, and the specific detection of COVID-19 (LOD: 4.57 × 102 copies/mL) by using the natural bed-receptor and a specific antibody in the point of care test.

scholarly journals Dual Electrochemical Sensing of Spiked Virus and SARS-CoV-2 Using Natural Bed-Receptor (MV-gal1)

2021 ◽  
Author(s):  
lham ghazizadeh ◽  
Ali Neshastehriz ◽  
Ali Dehghani Firoozabadi ◽  
Esmail Saievar-Iranizad ◽  
Samira Einali
Keyword(s):  
Specific Antibody ◽  
Electrochemical Sensing ◽  
Specific Detection ◽  
Early Screening ◽  
Lectin Receptor ◽  
Viral Particles ◽  
The One ◽  
First Time ◽  
Natural Bed ◽  
Virus Screening

Abstract It has been necessary to use methods that can detect the specificity of a virus during virus screening. In this study, we use a dual platform to identify any spiked virus and specific SARS-CoV-2 antigen, sequentially. We introduce a natural bed-receptor surface as Microparticle Vesicle-Galactins1 (MV-gal1) with the ability of glycan binding to screen every spiked virus. MV are the native vesicles which may have the gal-1receptor. Gal-1 is the one of lectin receptor which can bind to glycan. After dropping the MV-gal1 on the SCPE/GNP, the sensor is turned on due to the increased electrochemical exchange with [Fe(CN)6] -3/-4 probe. Dropping the viral particles of SARS-CoV-2 cause to turn off the sensor with covering the sugar bond (early screening). Then, with the addition of Au /Antibody-SARS-CoV-2 on the MV-gal1@ SARS-CoV-2 Antigen, the sensor is turned on again due to the electrochemical amplifier of AuNP (specific detection). As a result, our sensor has the capacity of screening of every spike virus, and the specific detection of covid-19 (LOD: 4.57 × 102 copies/mL) by using the natural bed-receptor and a specific antibody in the solid biosensor, for the first time.

scholarly journals Harmony COVID-19: a ready-to-use kit, low-cost detector, and smartphone app for point-of-care SARS-CoV-2 RNA detection

2021 ◽  
Author(s):  
Nuttada Panpradist ◽  
Enos Kline ◽  
Robert G Atkinson ◽  
Michael Roller ◽  
Qin Wang ◽  
...  
Keyword(s):  
Healthcare Workers ◽  
Point Of Care ◽  
Low Cost ◽  
High Viral Load ◽  
Respiratory Pathogens ◽  
Rna Detection ◽  
Point Of Care Test ◽  
Viral Transport ◽  
Viral Particles ◽  
First Time

RNA amplification tests sensitively detect SARS-CoV-2 infection, but their complexity and cost are prohibitive for expanding COVID-19 testing. We developed Harmony COVID-19, a point-of-care test using inexpensive consumables, ready-to-use reagents, and a simple device accommodating up to 4 samples simultaneously. Our ready-to-use, 4-plex reverse-transcription, loop-mediated isothermal amplification (RT-LAMP) can detect down to 0.38 SARS-CoV-2 RNA copies/μL and can report in 17 min for high viral load samples (5,000 copies/μL). Harmony detected 97% or 83% of contrived samples with ≥0.5 viral particles/μL in nasal matrix or saliva, respectively. Evaluation in clinical nasal specimens in viral transport media (VTM, n=101) showed 100% detection of RNA extracted from specimens with ≥0.5 SARS-CoV-2 RNA copies/μL, with 100% specificity in specimens positive for other respiratory pathogens. VTM is non-ideal for Harmony system, yet extraction-free analysis of VTM specimens (n=29) had 95% success in specimens with ≥1 RNA copies/μL. Usability testing performed first-time by healthcare workers showed 95% accuracy

Using a biomarker acutely to identify babies at risk of serious adverse effects from antibiotics: where is the ‘Terrible Moral and Medical Dilemma’?

2020 ◽  
pp. medethics-2020-107048
Author(s):  
Anneke M Lucassen ◽  
John Henry McDermott ◽  
William Newman
Keyword(s):  
At Risk ◽  
Adverse Effects ◽  
Point Of Care ◽  
Point Of Care Test ◽  
Pharmacogenetic Test ◽  
Loss Of Hearing ◽  
First Time

We thank Parker and Wright for engaging in this roundtable debate in such a spirited way. The ‘Pharmacogenetic [test] to Avoid Loss of Hearing’ (PALOH) Trial is the first time a genetic point of care test has been applied in the acute neonatal setting; therefore, it is not surprising that questions have been raised which require debate, discussion and clarification. Parker and Wright misattribute several assumptions to the roundtable authors, which we would like to clarify here. Since they raise wider questions about the PALOH trial itself, several of the roundtable discussants have made a joint response.

Rapid and specific detection of intact viral particles using functionalized microslit silicon membranes as a fouling-based sensor

The Analyst ◽  
2022 ◽  
Author(s):  
Michael E. Klaczko ◽  
Kilean Lucas ◽  
Alec T. Salminen ◽  
Molly C. McCloskey ◽  
Baturay Ozgurun ◽  
...  
Keyword(s):  
Gold Standard ◽  
Viral Infections ◽  
Point Of Care ◽  
Rapid Development ◽  
Specific Detection ◽  
Chain Reaction ◽  
The Public ◽  
Viral Particles ◽  
Accessible Point ◽  
Polymerase Chain

The COVID-19 pandemic demonstrated the public health benefits of reliable and accessible point-of-care (POC) diagnostic tests for viral infections. Despite the rapid development of gold-standard reverse transcription polymerase chain reaction...

scholarly journals Design and Development of Point of Care Test and Optical Reader for Early Screening of Kidney Related Disorder

2020 ◽  
Author(s):  
Pankaj Shihvare ◽  
Satyam Mohla ◽  
Tejal Dube ◽  
Alok Verma ◽  
Rohit Srivastava
Keyword(s):  
Point Of Care ◽  
Low Cost ◽  
Early Screening ◽  
Related Disorder ◽  
Detection Range ◽  
Spot Urine ◽  
Point Of Care Test ◽  
Optical Reader ◽  
Colorimetric Assays ◽  
Urine Testing

AbstractLow-cost, paper-based colorimetric assays for early screening of albumin, creatinine and their ratio have been developed. The developed methods are noninvasive and require only 10µl of the urine sample. A reflectance-based optical reader has also been developed for the quantification of the albumin and creatinine. The developed method is based on spot urine testing which is advantageous when compared to the conventional 24-hour urine collection. The detection range of albumin and creatinine assays is 10-150 mg/dl and 25–400 mg/dl, respectively. The developed assays and optical reader were tested with the chronic kidney diseased patient’s samples at KEM Hospital, Mumbai.

scholarly journals Reference Values of Thrombolastometry Parameters in Healthy Term Neonates

Children ◽  
2020 ◽  
Vol 7 (12) ◽  
pp. 259
Author(s):  
Martha Theodoraki ◽  
Rozeta Sokou ◽  
Serena Valsami ◽  
Zoi Iliodromiti ◽  
Abraham Pouliakis ◽  
...  
Keyword(s):  
Complete Blood Count ◽  
Point Of Care ◽  
Delivery Mode ◽  
Reference Ranges ◽  
Term Neonates ◽  
Point Of Care Test ◽  
Α Angle ◽  
The Impact ◽  
First Time ◽  
Clot Formation Time

Background: Thromboelastometry (ROTEM), as a point of care test, is an attractive tool for rapid evaluation of hemostasis. Currently, no reference ranges exist for all ROTEM assays in neonates, limiting its use in this vulnerable population. The aim of the present study was: (1) to establish reference ranges for standard extrinsically activated (EXTEM), intrinsically activated (INTEM), and fibrinogen polymerization (FIBTEM) ROTEM assays in whole blood samples of healthy term neonates; (2) to determine the impact of gender, delivery mode, and hematocrit on ROTEM parameters. Methods: EXTEM, INTEM, and FIBTEM ROTEM assays were performed simultaneously with complete blood count in 215 healthy term neonates. Results: Reference ranges (2.5th and 97.5th percentiles) were obtained for clotting time (CT), clot formation time (CFT), α-angle, clot firmness at 10 min (A10), maximum clot firmness (MCF), and lysis index at 60 min (LI60, %). Reference ranges for EXTEM were CT 38–78 s, CFT 49–148 s, A10 40–65 mm, and MCF 47–69 mm, LI60 83–98%. For INTEM, CT 134–270 s, CFT 50–142 s, A10 41–63 mm, and MCF 48–67 mm, LI60 85–97%, and finally, for FIBTEM: CT 36–85 s, A10 9–25 mm and MCF 10–26 mm, LI60 92–100%. Hematocrit values were positively correlated with CT, CFT and negatively with A10, MCF values. Conclusion: This study provides, for the first time, reference ranges for ROTEM EXTEM/INTEM/FIBTEM values simultaneously in healthy term neonates. The combined evaluation of ROTEM tests increases its diagnostic accuracy, contributing to the expansion of ROTEM use in the neonatal population.

scholarly journals Plateletworks® as a Point-of-Care Test for ASA Non-Sensitivity

2021 ◽  
Vol 11 (8) ◽  
pp. 813
Author(s):  
Hamzah Khan ◽  
Shubha Jain ◽  
Reid C. Gallant ◽  
Muzammil H. Syed ◽  
Abdelrahman Zamzam ◽  
...  
Keyword(s):  
Platelet Function ◽  
Cardiovascular Events ◽  
Light Transmission ◽  
Point Of Care ◽  
Platelet Function Test ◽  
Point Of Care Test ◽  
Discovery Phase ◽  
Function Test ◽  
Sensitivity Specificity ◽  
First Time

Aspirin (ASA) therapy is proven to be effective in preventing adverse cardiovascular events; however, up to 30% of patients are non-sensitive to their prescribed ASA dosage. In this pilot study, we demonstrated, for the first time, how ASA non-sensitivity can be diagnosed using Plateletworks®, a point-of-care platelet function test. Patients prescribed 81 mg of ASA were recruited in a series of two successive phases—a discovery phase and a validation phase. In the discovery phase, a total of 60 patients were recruited to establish a cut-off point (COP) for ASA non-sensitivity using Plateletworks®. Each sample was simultaneously cross-referenced with a light transmission aggregometer (LTA). Our findings demonstrated that >52% maximal platelet aggregation using Plateletworks® had a sensitivity, specificity, and likelihood ratio of 80%, 70%, and 2.67, respectively, in predicting ASA non-sensitivity. This COP was validated in a secondary cohort of 40 patients prescribed 81 mg of ASA using Plateletworks® and LTA. Our data demonstrated that our established COP had a 91% sensitivity and 69% specificity in identifying ASA non-sensitivity using Plateletworks®. In summary, Plateletworks® is a point-of-care platelet function test that can appropriately diagnose ASA non-sensitive patients with a sensitivity exceeding 80%.

Testing for resistance: Point-of-care testing as a communicational tool in antibiotic prescribing

2018 ◽  
Vol 14 (3) ◽  
pp. 229-240
Author(s):  
Johanna Lindell
Keyword(s):  
Point Of Care ◽  
Rapid Test ◽  
Antibiotic Use ◽  
Treatment Recommendation ◽  
Antibiotic Prescribing ◽  
Communicative Practices ◽  
Effective Strategies ◽  
Reactive Protein ◽  
Point Of Care Test ◽  
Test Result

As antibiotic resistance becomes a growing health emergency, effective strategies are needed to reduce inappropriate antibiotic use. In this article, one such strategy – communicative practices associated with the C-reactive protein point-of care test – is investigated. Building on a collection of 31 videorecorded consultations from Danish primary care, and using conversation analysis, this study finds that the rapid test can be used throughout the consultation to incrementally build the case for a nonantibiotic treatment recommendation, both when the test result is forecast and reported. The study also finds that the format of reports of elevated results differs from that of ‘normal’ results, resulting in a subtle shift of authority from doctor to test.

Sign in / Sign up

Export Citation Format

Share Document